
Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Stocks | 100.970 | 100.970 | 0.000 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 19.122 | 20.453 |
Price to Book | 3.351 | 4.071 |
Price to Sales | 2.281 | 2.455 |
Price to Cash Flow | 17.205 | 16.429 |
Dividend Yield | 1.209 | 1.361 |
5 Years Earnings Growth | 12.704 | 12.134 |
Number of long holdings: 57
Number of short holdings: 1
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
UnitedHealth | US91324P1021 | 6.02 | 523.20 | +0.02% | |
Medincell | FR0004065605 | 4.91 | 14.00 | -1.55% | |
Eli Lilly | US5324571083 | 4.09 | 818.22 | +1.61% | |
Boston Scientific | US1011371077 | 3.46 | 100.05 | -1.18% | |
Becton Dickinson | US0758871091 | 3.19 | 226.42 | +0.17% | |
Thermo Fisher Scientific | US8835561023 | 2.87 | 489.06 | +1.26% | |
Merck&Co | US58933Y1055 | 2.73 | 86.59 | -0.61% | |
Novartis | CH0012005267 | 2.59 | 96.82 | -1.63% | |
Fresenius SE | DE0005785604 | 2.42 | 39.500 | +0.05% | |
Sanofi | FR0000120578 | 2.28 | 100.40 | -1.59% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Pluvalca Disruptive Opportunities A | 98.54M | 3.71 | -6.87 | - | ||
Pluvalca France Small Caps A | 65.98M | 2.84 | -1.67 | 4.08 | ||
Pluvalca Initiatives PME A | 67.39M | 5.55 | -4.69 | 6.94 | ||
Pluvalca Allcaps A | 53.3M | 8.69 | 4.70 | 5.39 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review